Graves病相关性胆汁淤积症的临床特征

莫娟; 傅蕾; 郑宜翔; 彭仕芳

doi:10.11817/j.issn.1672-7347.2021.200004

您当前的位置：

首页 >

文章列表页 >

Graves病相关性胆汁淤积症的临床特征

扫描看全文

文章被引用时，请邮件提醒。

提交

论著 | 更新时间：2023-06-07

Graves病相关性胆汁淤积症的临床特征
Clinical characteristics of Graves’ disease associated cholestasis
中南大学学报(医学版) 中南大学学报(医学版) 2021年46卷第1期页码：47-52
作者机构：

1.中南大学湘雅医院感染科，长沙 410008
作者简介：

莫娟，Email: 642533771@qq.com, ORCID: 0000-0002-4478-8405
彭仕芳，Email: sfp1988@csu.edu.cn, ORCID: 0000-0003-4229-0299
基金信息：

国家自然科学基金(81770623;81974080);湖南省自然科学基金(2018JJ2657);湘雅医院临床研究基金(2016L10)
DOI：10.11817/j.issn.1672-7347.2021.200004
中图分类号：
CSTR：

莫娟, 傅蕾, 郑宜翔, 等. Graves病相关性胆汁淤积症的临床特征[J]. 中南大学学报(医学版), 2021,46(1):47-52.

MO Juan, FU Lei, ZHENG Yixiang, et al. Clinical characteristics of Graves’ disease associated cholestasis[J]. Journal of Central South University. Medical Science, 2021,46(1):47-52.
莫娟, 傅蕾, 郑宜翔, 等. Graves病相关性胆汁淤积症的临床特征[J]. 中南大学学报(医学版), 2021,46(1):47-52. DOI： 10.11817/j.issn.1672-7347.2021.200004.

MO Juan, FU Lei, ZHENG Yixiang, et al. Clinical characteristics of Graves’ disease associated cholestasis[J]. Journal of Central South University. Medical Science, 2021,46(1):47-52. DOI： 10.11817/j.issn.1672-7347.2021.200004.

摘要

目的,2,多种原因可导致胆汁淤积，而由Graves病引起的胆汁淤积在临床上极易被忽视。本研究旨在分析Graves病相关性胆汁淤积的临床特点，以提高对该种临床综合征的认识及诊治水平。,方法,2,回顾性分析2000年1月至2018年12月入住湘雅医院感染科的Graves病相关性胆汁淤积症的13例患者，收集并分析其年龄、性别、肝功能、甲状腺功能、凝血功能、心脏特殊检查、治疗情况及随访资料。,结果,2,13例患者中男10例，女3例，年龄33~55(中位数43)岁，均有黄疸、瘙痒及高代谢症状。入院时实验室检查示：总胆红素(total bilirubin，TBIL)170.4~976.7(中位数388.8) µmol/L，直接胆红素(direct bilirubin，DBIL)93.2~418.1(中位数199.2) µmol/L，谷丙转氨酶25.1~182.1(中位数106.4) U/L，谷草转氨酶38.2~265.7(中位数59.7) U/L，碱性磷酸酶(alkaline phosphatase，ALP)105.3~332.0(中位数184.5) U/L，谷氨酰基转移酶20.7~345.1(中位数47.6) U/L；游离三碘甲腺原氨酸(free triiodothyronine，FT,3,)为4.1~50.0(中位数21.6) pmol/L，血清游离甲状腺素(free thyroxine，FT,4,)为30.4~100.0(中位数87.9) pmol/L，促甲状腺激素受体抗体为4.2~40(中位数19.8) U/mL；患者凝血功能、射血分数及心脏大小正常。经抗甲状腺功能亢进治疗后，患者的FT,3,和FT,4,下降，TBIL明显降低。通过电话询问患者出院后6个月皮肤症状及甲状腺功能和肝功能检查结果，所有患者FT,3,、FT,4,及TBIL恢复正常，皮肤瘙痒症状消失。,结论,2,Graves病相关性胆汁淤积症发病率低。随着Graves病的有效控制，胆汁淤积可明显好转乃至消失。Graves病引起的胆汁淤积可能为体质特异性，对于甲状腺功能亢进的胆汁淤积表现者的鉴别诊断应将Graves病考虑在内。

Abstract

Objective,2,A variety of causes can lead to cholestasis, however, cholestasis caused by Graves’ disease is usually overlooked clinically. Here we analyze the clinical characteristics of Graves’ disease associated cholestasis so as to have a better understanding for the disease.,Methods,2,We retrospectively collected 13 inpatients’ data who suffered from the Graves’ disease associated cholestasis in the Department of Infectious Disease of Xiangya Hospital from January 2000 to December 2018. The characteristics of the patients’ age, gender, liver function, thyroid function, coagulation function, the special cardiac examination, treatment, and follow-up data were analyzed.,Results,2,Thirteen patients, including 10 males and 3 females with the age range from 33 to 55 (median 43) years old presented cholestasis, pruritus, and hypermetabolic symptoms. The levels of total bilirubin (TBIL), direct bilirubin (DBIL), glutamic-pyruvic transferase, glutamic-oxaloacetic transferase, alkaline phosphosphatase, and gamma glutamyl transpeptidase were 170.4-976.7 (median 388.8) µmol/L, 93.2-418.1 (median 199.2) µmol/L, 25.1-182.1 (median 106.4) U/L, 38.2-265.7 (median 59.7) U/L, 105.3-332.0 (median 184.5) U/L, and 20.7-345.1 (median 47.6) U/L, respectively. The levels of free triiodothyronine (FT,3,), free thyroxine (FT,4,), and thyrotrophin receptor antibody were 4.1-50.0 (median 21.6) pmol/L, 30.4-100.0 (median 87.9) pmol/L, and 4.2-40 (median 19.8) U/mL, respectively. All patients’ coagulation function, heart size, and ejection fraction (EF) value were normal. After anti-thyroid treatment, the levels of FT,3, FT,4, and TBIL decreased. Through telephone interview, we were able to know that after 6 months of anti-thyroid treatment, the level of FT,3, FT,4, and TBIL in these patients returned to normal, and the itch symptom disappeared completely.,Conclusion,2,Graves’ disease can cause cholestasis, with the low incidence. The symptoms of cholestasis can be improved or even eradicated with the cure of the Graves’ disease. The cholestasis may be idiopathic. For patients with cholestasis and hyperthyroidism, Graves’ disease should be considered for differential diagnosis.

关键词

Graves病胆汁淤积Graves病相关性胆汁淤积临床表现诊断治疗

Keywords

Graves’ diseasecholestasisGraves’ disease associated cholestasisclinical manifestationdiagnosistreatment

references

Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis: facts and fiction[J]. Hepatology, 2014, 60(1): 399-407.

Chen K, Xie Y, Zhao L, et al. Hyperthyroidism-associated hypercalcemic crisis: A case report and review of the literature[J]. Medicine, 2017, 96(4): e6017.

雷翔, 许雪亮. 甲状腺相关眼病患者与正常人眼眶前脂肪细胞表面抗原表的比较[J]. 中南大学学报(医学版), 2008, 33(1): 43-46.

LEI Xiang, XU Xueliang. Cell surface antigen expression of orbital preadipocytes between patients with thyroid-associated ophthalmopathy and health adults[J]. Journal of Central South University. Medical Science, 2008, 33(1): 43-46.

De Leo S, Lee SY, Braverman LE. Hyperthyroidism[J]. Lancet, 2016, 388(10047): 906-918.

周伏喜, 卢放根, 凌奇荷. 消化科门诊中甲亢患者的临床特征(附42例病例分析)[J]. 中国医师杂志, 2003, 5(8): 1103-1103.

ZHOU Fuxi, LU Fanggen, LING Qihe. Clinical characteristics of hyperthyroidism in gastroenterology clinical (analysis of 42 cases)[J]. Journal of Chinese Physician, 2003, 5(8): 1103-1103.

Ashkar FS, Miller R, Smoak WM, et al. Liver disease in hyperthyroidism[J]. South Med J, 1971, 64(4): 462-465.

Nieri S, Riccardo GG, Salvadori G, et al. Primary biliary cirrhosis and Graves’ disease[J]. J Clin Gastroenterol, 1985, 7(5): 434-437.

Joseph DC, Yao J D, Gross J, et al. Cholestatic jaundice in hyperthyroidism[J]. Am J Med, 1989, 86(1): 619-620.

Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperhyroidism and other causes of thyrotoxicosis[J]. Thyroid, 2016, 26(10): 1343-1421.

Huang MJ, Liaw YF. Clinical associations between thyroid and liver disease[J]. J Gastroenterol Hepatol, 1995, 10(3): 344-350.

Thompson WG, Hart IR. Chronic active hepatitis and Graves’ disease[J]. Am J Dig Dis, 1973, 18(2): 111-119.

Biscoveanu M, Hasinski S. Abnormal results of liver function tests in patients with Graves' disease[J]. Endocr Pract, 2000, 6(5): 367-369.

Khemichian S, Fong TL. Hepatic dysfunction in hyperthyroidism[J]. Gastroenterol Hepatol (NY), 2011, 7(5): 337-339.

Barnes SC, Wicking JM, Johnston JD. Graves’ disease presenting with cholestatic jaundice[J]. Ann Clin Biochem, 1999, 36(5): 677-679.

Sola J, Pardo-Mindán J, Zozaya J, et al. Liver changes in patients with hyperthyroidism[J]. Liver International, 1991, 11(4): 193-197.

Dooner HP, Parada J, Aliaga C, et al. The liver in thyrotoxicosis[J]. Arch Intern Med, 1967, 120(1): 25.

段然, 李静. 甲状腺功能亢进症合并肝损害的鉴别诊断和处理[J]. 中国实用内科杂志, 2018, 38(10): 971-973.

DUAN Ran, LI Jing. Differential diagnosis and treatment of hyperthyroidism combined with liver injury[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(10): 971-973.

Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Intern, 2017, 11(3): 221-241.

Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex[J]. Hepatology, 2009, 49(6): 2001-2009.

Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury[J]. World J Gastroenterol, 2008, 14(44): 6774-6785.

Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis[J]. Hepatology, 2006, 44(4): 778-787.

Fernández-Murga ML, Petrov PD, Conde I, et al. Advances in drug-induced cholestasis: clinical perspectives, potential mechanisms and in vitro systems[J]. Food Chem Toxicol, 2018, 120:196-212.

Silverman E, Haber L, Geha R. Lift then shift: Thyrotoxic periodic paralysis[J]. Am J Med, 2019, 132(1): e3-e6.

浏览量

下载量

CSCD

工具集

关联资源

13例累及肺部的嗜酸性肉芽肿性多血管炎的临床特征

15例成人肺朗格汉斯细胞组织细胞增生症临床分析及文献回顾

创伤后骨髓炎的诊治进展

甲状腺骨外尤因肉瘤1例并文献复习

小脑发育不良性神经节细胞瘤1例及文献复习